Investigational drug · Phase 3
Tozorakimab
Also called: MEDI3506
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
2 still active
All registered trials
10
Any phase or sponsor naming "Tozorakimab"
First trial start
2022
Jan 3, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tozorakimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
- Viral Lung Infection and Acute Respiratory Failure
Approved drugs for the same conditions: Asthma · COPD · Infectious disease and vaccines · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "Tozorakimab" as an intervention, largest first.
- Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental OxygenPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT05624450 · 3,527 participants (planned) · Start Dec 13, 2022 · Primary completion Nov 4, 2027
Drug: Tozorakimab; Placebo · For: Viral Lung Infection and Acute Respiratory Failure
Sites: Birmingham, Alabama; Mobile, Alabama; Phoenix, Arizona · 473 sites in all
- Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06040086 · 1,454 participants · Start Sep 22, 2023 · Primary completion Mar 6, 2026
Drug: Placebo; Tozorakimab · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Birmingham, Alabama; Decatur, Alabama; Sheffield, Alabama · 368 sites in all
- Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.Pivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05158387 · 1,172 participants · Start Feb 7, 2022 · Primary completion Jan 19, 2026
Drug: Tozorakimab; Tozorakimab and 1 more · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Sheffield, Alabama; Lincoln, California; Newport Beach, California · 212 sites in all
- Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT05166889 · 1,132 participants · Start Jan 3, 2022 · Primary completion Jan 19, 2026
Drug: Tozorakimab; Tozorakimab and 1 more · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Huntsville, Alabama; Mobile, Alabama; Montgomery, Alabama · 212 sites in all
- Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled CorticosteroidsPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06932263 · 540 participants (planned) · Start Mar 26, 2025 · Primary completion Jun 7, 2027
Drug: Tozorakimab; Placebo · For: Asthma
Sites: Bakersfield, California; Huntington Beach, California; La Mesa, California · 223 sites in all
- An Accessorised Prefilled Syringe to an Autoinjector Pharmacokinetic Bridging Study of TozorakimabPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06908577 · 254 participants · Start Apr 7, 2025 · Primary completion Nov 25, 2025
Drug: Tozorakimab · For: Healthy Participants
Sites: Glendale, California; Baltimore, Maryland; Berlin, Germany · 4 sites in all
- A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic BronchitisPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT04631016 · 137 participants · Start Dec 14, 2020 · Primary completion May 30, 2023
Drug: Tozorakimab · For: Chronic Obstructive Pulmonary Disease (COPD); Chronic Bronchitis
Sites: Sheffield, Alabama; Newport Beach, California; Newark, Delaware · 90 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06897748 · 98 participants · Start Apr 12, 2025 · Primary completion Apr 21, 2026
Drug: Placebo; Tozorakimab · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Aramil, Russia; Izhevsk, Russia; Moscow, Russia · 12 sites in all
- Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of ExacerbationsPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07566195 · 59 participants (planned) · Start May 5, 2026 · Primary completion Dec 29, 2028
Drug: Tozorakimab Dose Regimen 1; Tozorakimab Dose Regimen 2 · For: Chronic Obstructive Pulmonary Disease; COPD
Sites: Aix-en-Provence, France; Brest, France; Colmar, France · 13 sites in all
AstraZenecaAstraZeneca (AZN)
NCT06304961 · 46 participants · Start Apr 8, 2024 · Primary completion Sep 9, 2024
Drug: Tozorakimab · For: Healthy Participants
Sites: Berlin, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Structures of clinical antibodies bound to IL-33 uncover two distinct epitopes underlying differential efficacy.
Chen J, Wang Y, Wang X · MAbs 2026
- Reimagining COPD treatment: are biologics the next frontier?
Rogliani P, De Guido I, Gholamalishahi S, et al. · Expert Opin Pharmacother 2026
- Understanding the roles of interleukin-33: is there promise for therapeutic targeting?
Gao X, Yu Y, Zhong S, et al. · Expert Opin Ther Targets 2026
- Tozorakimab to Prevent COPD Exacerbations.
Sciurba FC, Watz H, Bourdin A, et al. · N Engl J Med 2026
- COPD: real-world evidence on single-inhaler triple therapy and the emergence of biologic therapy.
Da Re B, Reccardini N, Monteleone G, et al. · Front Pharmacol 2026
- Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies.
Raman S, Rahman S, Polverino F, et al. · Eur J Clin Invest 2026
Also in development for Chronic Obstructive Pulmonary Disease (COPD)
- HSK39004 DryPhase 34 trials
Haisco Pharmaceutical Group Co., Ltd. · Chronic Obstructive Lung Disease (COLD), COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD)
- AstegolimabPhase 33 trials
Roche (Genentech) · Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD)
- HSK31858Phase 33 trials
Haisco Pharmaceutical Group Co., Ltd. · Non-cystic Fibrosis Bronchiectasis, Asthma Bronchiale, Bronchiectasis
- HSK39004 Dry SimulantPhase 32 trials
Haisco Pharmaceutical Group Co., Ltd. · COPD (Chronic Obstructive Pulmonary Disease), Chronic Obstructive Pulmonary Disease (COPD)
- JKN2401Phase 31 trial
Joincare Pharmaceutical Group Industry Co., Ltd · Chronic Obstructive Pulmonary Disease (COPD)
- PRA-216Phase 22 trials
Prana Therapies Inc · Chronic Obstructive Pulmonary Disease (COPD), Mild to Moderate Asthma
- AZD6793Phase 21 trial
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD)
- EXPD-101FXS7553Phase 21 trial
Expedition Therapeutics, Inc · Chronic Obstructive Pulmonary Disease (COPD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.